Core Viewpoint - BioPorto A/S has successfully completed a private placement of 40,438,426 new shares, raising approximately DKK 43 million, which will enhance the company's financial flexibility to pursue strategic priorities and strengthen its commercial platform [1][2]. Group 1: Private Placement Details - The private placement involved 40,438,426 new shares and is expected to generate gross proceeds of around DKK 43 million [1][2]. - The subscription price for the new shares is scheduled to be paid by 24 November 2025, with the share capital increase registration to follow shortly thereafter [2]. - BioPorto anticipates that the new shares will be listed on Nasdaq Copenhagen A/S by no later than 26 November 2025 [2]. Group 2: Strategic Implications - The funds raised will support the completion of data collection, submission of a pre-submission to the FDA, and initiation of a Validation Study in the U.S. clinical trial [2]. - The Board of BioPorto has considered various future financing options, including potential divestments of non-core assets and credit facilities, to ensure a balanced funding structure [2]. - The company aims to position itself for positive cash flow by the second half of 2027 [2]. Group 3: Company Overview - BioPorto specializes in in vitro diagnostics, focusing on actionable kidney biomarkers to improve patient management and outcomes [4][5]. - The flagship products are based on the NGAL biomarker, which aids in the risk assessment and management of Acute Kidney Injury (AKI) [5]. - BioPorto's tests are marketed under various registrations, including CE mark and FDA clearance for ProNephro AKI™ in the U.S. [5].

13 November 2025 Announcement no. 24 THIS ANNOUNCEMENT IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE A PROSPECTUS OR A PUBLIC OFFER OF THE SECURITIES DESCRIBED HEREIN NOR IS IT AN OFFER TO SELL OR ISSUE, OR A SOLICITATION OF AN OFFE ...

July 28, 2025 News Release BioPorto attends the Association for Diagnostics & Laboratory Medicine meeting, where NGAL and Acute Kidney Injury will be a key focus among participants. Laboratory medicine continues to focus on kidney diagnostics. ADLM education for members includes an online 2024 event recording which highlighted Dr. Prasad Devarajan speaking on the Use of the new Biomarker NGAL in Acute Kidney Injury. There is expected continued interest and awareness on AKI throughout 2025 and 2026 due to th ...